Misplaced Pages

LY-320,135

Identifiers
IUPAC name 4-benzonitrile
CAS Number	176977-56-3
PubChem CID	5311257
IUPHAR/BPS	742
ChemSpider	4470772
UNII	CJY03984CT
ChEMBL	ChEMBL411481
CompTox Dashboard (EPA)	DTXSID901027464
ECHA InfoCard	100.190.302
Chemical and physical data
Formula	C24H17NO4
Molar mass	383.403 g·mol
3D model (JSmol)	Interactive image
SMILES c3cc(OC)ccc3-c2oc1cc(OC)ccc1c2C(=O)c4ccc(C#N)cc4
InChI InChI=1S/C24H17NO4/c1-27-18-9-7-17(8-10-18)24-22(20-12-11-19(28-2)13-21(20)29-24)23(26)16-5-3-15(14-25)4-6-16/h3-13H,1-2H3 Key:RYNSGDFWBJWWSZ-UHFFFAOYSA-N
(verify)

LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB₁. It was developed by Eli Lilly and Company in the 1990s.

LY-320,135 displays fairly good selectivity, with a binding affinity for CB₁ around 70x stronger than for CB₂, but both its potency and selectivity are modest compared to newer agents, and at higher doses it also binds to a range of non-cannabinoid receptors. However LY-320,135 is still fairly widely used in research, particularly for elucidating the mechanisms by which many CB₁ antagonists act as inverse agonists at higher doses.

References

1. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, et al. (January 1998). "LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation". The Journal of Pharmacology and Experimental Therapeutics. 284 (1): 291–7. PMID 9435190.
2. Pertwee RG (February 2005). "Inverse agonism and neutral antagonism at cannabinoid CB1 receptors". Life Sciences. 76 (12): 1307–24. doi:10.1016/j.lfs.2004.10.025. PMID 15670612.

This cannabinoid related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Cannabinoids
• CB1 receptor antagonists
• Benzofuran ethers at the benzene ring
• Resorcinol ethers
• Aromatic ketones
• Benzonitriles
• Drugs developed by Eli Lilly and Company
• Cannabinoid stubs